Navigation Links
EMAS publishes position statement about the post-reproductive health of women
Date:5/17/2011

Amsterdam, 17 May 2011 - Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society (EMAS) in the journal Maturitas (http://www.maturitas.org/) on managing menopausal women with a personal or family history of venous thromboembolism (VTE). The statement includes summary recommendations as a quick aid for the busy clinician.

"The expanding ageing female population means that clinicians increasingly have to deal with post-reproductive health problems," said Professor Serge Rozenberg, President of EMAS. "EMAS has risen to the challenge and is providing clear guidance on the position statements covering hormone and non hormone therapy (HT) options, as well as complementary and alternative therapies."

The statement will be published in the June 2011 issue:

Venous thromboembolism, including deep venous thrombosis (DVT) and pulmonary embolism (PE), is a serious cardiovascular event whose incidence rises with increasing age. Randomized controlled trials have shown an increased risk of VTE in oral hormone therapy (HT) users. There are no randomized trial data on the effect of transdermal estrogen on VTE. Recent observational studies and meta-analyses suggest that transdermal estrogen does not increase VTE risk. These clinical observations are supported by experimental data showing that transdermal estrogen has a minimal effect on hepatic metabolism of hemostatic proteins as the portal circulation is bypassed.

A personal or family history of VTE, especially in individuals with a prothrombotic mutation, is a strong contraindication to oral HT but transdermal estrogen can be considered after careful individual evaluation of the benefits and risks. Transdermal estrogen should be also the first choice in overweight/obese women requiring HT. Observational studies suggest that micronized progesterone and dydrogesterone might have a better risk profile than other progestins with regard to VTE risk.

Although these findings should be confirmed by randomized clinical trials, they strongly suggest that both the route of estrogen administration and the type of progestin may be important determinants of the overall benefit-risk profile of HT.


'/>"/>

Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Source:Eurekalert

Related medicine news :

1. ASTRO publishes evidence-based guideline for thoracic radiotherapy
2. Canadian Journal of Cardiology publishes advice on genetic testing of inherited cardiac arrhythmias
3. NYSCF - Robertson investigator publishes research to better understand pluripotent stem cells
4. ASTRO publishes palliative radiotherapy for bone metastases guideline
5. Practical Radiation Oncology publishes first issue
6. EMAS publishes position statements about the post-reproductive health of women
7. ASTRO publishes whole breast irradiation guidelines
8. ESMO publishes updated guidelines on cancer care
9. US Medical Supplies Publishes 2010 Catalog
10. AACR Adds to Growing STAR P-2 trial; Publishes Update and Perspectives in Cancer Prevention Research
11. Better Hearing Institute Publishes Comprehensive Consumer Guide to Buying Hearing Aids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... the Wharton Seminars for Business Journalists , led by the Wharton ... business and economic issues.  This one-day program at the Wharton School’s San ...
(Date:5/5/2016)... ... May 05, 2016 , ... An ... all U.S. states and certain Canadian provinces is now available from the International ... Institute (WCRI). , The report, Workers’ Compensation Laws as of January ...
(Date:5/5/2016)... Dubuque, IA (PRWEB) , ... May 05, 2016 ... ... his insurance agency’s ongoing community enrichment program serving families of greater Dubuque, IA. ... area’s active duty, reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of ... hair loss treatment. Dr. Stong is double board certified and the only facial ... the treatment of hair loss. Non-surgical therapies such as stem cells can be used ...
(Date:5/5/2016)... YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses Week ... job seeking nurses and healthcare employers. With their enrollment into the Talent Tech Lab ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities ... ... ... ... ...
(Date:5/3/2016)... Ore. , May 3, 2016   ... medical technology, today announced Food and Drug Administration ... resynchronization defibrillator that provides heart failure patients with ... Iperia devices also have remote monitoring with daily ... adapts the heart rate in response to physiological ...
(Date:5/3/2016)...   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month ... patients who tell their personal story and encourage those at risk to get tested and ... C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology: